LEXX (Lexaria Bioscience) LT-Debt-to-Total-Asset : 0.01 (As of May. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lexaria Bioscience's long-term debt to total assests ratio for the quarter that ended in May. 2024 was 0.01.

Lexaria Bioscience's long-term debt to total assets ratio declined from May. 2023 (0.03) to May. 2024 (0.01). It may suggest that Lexaria Bioscience is progressively becoming less dependent on debt to grow their business.

Lexaria Bioscience LT-Debt-to-Total-Asset Historical Data

The historical data trend for Lexaria Bioscience's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience LT-Debt-to-Total-Asset Chart

Lexaria Bioscience Annual Data

Trend

Oct13

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

Lexaria Bioscience Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.04	0.04	0.02	0.01

Lexaria Bioscience LT-Debt-to-Total-Asset Calculation

Lexaria Bioscience's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2023 is calculated as

LT Debt to Total Assets (A: Aug. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Aug. 2023 )	/	Total Assets (A: Aug. 2023 )
	=	0.136	/	3.084
	=	0.04

Lexaria Bioscience's Long-Term Debt to Total Asset Ratio for the quarter that ended in May. 2024 is calculated as

LT Debt to Total Assets (Q: May. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: May. 2024 )	/	Total Assets (Q: May. 2024 )
	=	0.115	/	10.018
	=	0.01

Lexaria Bioscience (NAS:LEXX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lexaria Bioscience LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Executives

Catherine C. Turkel	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Vanessa Carle	officer: Secretary	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Gregory Downey	officer: Chief Financial Officer	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka	director, 10 percent owner, officer: CEO	1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Reese Albert L Jr	director
Brian W. Quigley	director	100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie	director	305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger	officer: CFO	8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty	director, 10 percent owner	23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar	director, officer: CFO	604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter	director	220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford	director	888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke	officer: Sr. VP, Business Development	38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini	director, 10 percent owner	11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan	director, officer: Vice President - Corp Develop	SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6